PDPierre-Yves Desprez

Pierre-Yves Desprez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Pierre-Yves Desprez has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Yoko Itahana

    California Pacific Medical Center, Cancer Research Institute, San Francisco, California

    4 shared publications
  • Jarnail Singh

    California Pacific Medical Center, Cancer Research Institute, San Francisco, CA 94115

    3 shared publications
  • Claudia Qiao Lin

    From the ‡Geraldine Brush Cancer Research Institute, California Pacific Medical Center, San Francisco, California 94115 and the §Department of Cell and Molecular Biology, Lawrence Berkeley National Laboratory, Berkeley, California 94720

    2 shared publications
  • James L. Bennington

    California Pacific Medical Center, Cancer Research Institute, San Francisco, California

    2 shared publications
  • Jean-Philippe Coppe

    California Pacific Medical Center, Cancer Research Institute, San Francisco, California 94115, USA

    2 shared publications
  • Judith Campisi

    From the ‡Geraldine Brush Cancer Research Institute, California Pacific Medical Center, San Francisco, California 94115 and the §Department of Cell and Molecular Biology, Lawrence Berkeley National Laboratory, Berkeley, California 94720

    2 shared publications

Latest Publications

  • Id-1 and Id-2 Proteins as Molecular Markers for Human Prostate Cancer Progression

    by Jean-Philippe Coppe, Yoko Itahana, Dan H. Moore, James L. Bennington, Pierre-Yves Desprez

    Purpose: Id proteins are dominant-negative regulators of basic helix-loop-helix transcription factors that control malignant cell behavior in many different tissues. This study aimed to identify the potential role of Id-1 and Id-2 proteins as molecular makers for prostate cancer progression. Experimental Design: Using the technique of immunohistochemistry, we determined Id-1 and Id-2 expression in a panel of 67 human prostate biopsies. We also manipulated Id-1 and Id-2 expression in LNCaP and PC3 prostate cancer cell lines and determined the effects on invasion in vitro, matrix metalloproteinase secretion, and proliferation. Results: Both Id-1 and Id-2 proteins were up-regulated during human prostate cancer progression in vivo and were overexpressed in highly aggressive prostate cancer cells. In vitro, constitutive expression of Id-1, and to a lesser extent Id-2, converted nonaggressive LNCaP prostate cancer cells into more proliferative and invasive cells and increased their secretion of matrix metalloproteinases. Conversely, the down-regulation of Id-2 expression in highly metastatic PC3 cells reduced their growth potential and invasiveness. Conclusions: We propose that both Id-1 and Id-2 proteins control prostate cancer cell phenotypes and could serve as molecular markers of aggressive human prostate cancer.


  • Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis

    by Sylvia Fong, Yoko Itahana, Tomoki Sumida, Jarnail Singh, Jean-Philippe Coppe, Yong Liu, Peter C. Richards, James L. Bennington, Nancy M. Lee, Robert J. Debs, et al.

    Mammary epithelial cells constitutively expressing Id-1 protein are unable to differentiate, acquire the ability to proliferate, and invade the extracellular matrix. In addition, Id-1 is aberrantly over-expressed in aggressive and metastatic breast cancer cells, as well as in human breast tumor biopsies from infiltrating carcinomas, suggesting Id-1 might be an important regulator of breast cancer progression. We show that human metastatic breast cancer cells become significantly less invasive in vitro and less metastatic in vivo when Id-1 is down-regulated by stable transduction with antisense Id-1. Expression of the matrix metalloproteinase MT1-MMP is decreased in proportion to the decrease in Id-1 protein levels, representing a potential mechanism for the reduction of invasiveness. Further, to more accurately recapitulate the biology of and potential therapeutic approaches to tumor metastasis, we targeted Id-1 expression systemically in tumor-bearing mice by using a nonviral approach. We demonstrate significant reduction of both Id-1 and MT1-MMP expressions as well as the metastatic spread of 4T1 breast cancer cells in syngeneic BALB/c mice. In conclusion, our studies have identified Id-1 as a critical regulator of breast cancer progression and suggest the feasibility of developing novel therapeutic approaches to target Id-1 expression to reduce breast cancer metastasis in humans.


  • Helix-Loop-Helix Proteins in Mammary Gland Development and Breast Cancer

    by Pierre-Yves Desprez, Tomoki Sumida, Jean-Philippe Coppé

    The basic helix-loop-helix (bHLH) family of transcription factors functions in the coordinated regulation of gene expression, cell lineage commitment, and cell differentiation in most mammalian...


  • Constitutive expression of the Id-1 promoter in human metastatic breast cancer cells is linked with the loss of NF-1/Rb/HDAC-1 transcription repressor complex

    by Jarnail Singh, Kenji Murata, Yoko Itahana, Pierre-Yves Desprez

    Oncogene is one of the world’s leading cancer journals. It is published weekly and covers all aspects of the structure and function of Oncogenes. Oncogene also publishes 8 Reviews issues a year, on a broad range of topics.


  • Open Access

    Id-1, ITF-2, and Id-2 Comprise a Network of Helix-Loop-Helix Proteins That Regulate Mammary Epithelial Cell Proliferation, Differentiation, and Apoptosis

    by Simona Parrinello, Claudia Qiao Lin, Kenji Murata, Yoko Itahana, Jarnail Singh, Ana Krtolica, Judith Campisi, Pierre-Yves Desprez


  • A Novel Pathway for Mammary Epithelial Cell Invasion Induced by the Helix-Loop-Helix Protein Id-1

    by Pierre-Yves Desprez, Claudia Qiao Lin, Nicole Thomasset, Carolyn J. Sympson, Mina J. Bissell, Judith Campisi

    Mammary epithelial cells undergo changes in growth, invasion, and differentiation throughout much of adulthood, and most strikingly during pregnancy, lactation, and involution. Although the pathways of milk protein expression are being elucidated, little is known, at a molecular level, about control of mammary epithelial cell phenotypes during normal tissue morphogenesis and evolution of aggressive breast cancer. We developed a murine mammary epithelial cell line, SCp2, that arrests growth and functionally differentiates in response to a basement membrane and lactogenic hormones. In these cells, expression of Id-1, an inhibitor of basic helix-loop-helix transcription factors, declines prior to differentiation, and constitutive Id-1 expression blocks differentiation. Here, we show that SCp2 cells that constitutively express Id-1 slowly invade the basement membrane but remain anchorage dependent for growth and do not form tumors in nude mice. Cells expressing Id-1 secreted a ∼120-kDa gelatinase. From inhibitor studies, this gelatinase appeared to be a metalloproteinase, and it was the only metalloproteinase detectable in conditioned medium from these cells. A nontoxic inhibitor diminished the activity of this metalloproteinase in vitro and repressed the invasive phenotype of Id-1-expressing cells in culture. The implications of these findings for normal mammary-gland development and human breast cancer were investigated. A gelatinase of ∼120 kDa was expressed by the mammary gland during involution, a time when Id-1 expression is high and there is extensive tissue remodeling. Moreover, high levels of Id-1 expression and the activity of a ∼120-kDa gelatinase correlated with a less-differentiated and more-aggressive phenotype in human breast cancer cells. We suggest that Id-1 controls invasion by normal and neoplastic mammary epithelial cells, primarily through induction of a ∼120-kDa gelatinase. This Id-1-regulated invasive phenotype could contribute to involution of the mammary gland and possibly to the development of invasive breast cancer.